drugset / Trial / NCT00403039
Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema
Phase 1
Completed
41 enrolled
Vitreous -Retina- Macula Consultants of New York
Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine the effects of Lucentis for active Central Retinal Vein Occlusion with Macular Edema
Timeline
- Start
- 2006-11
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |